SCHEMBL4419288

SCHEMBL4419288

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
TSHR P16473 3/20 0.59
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HTT P42858 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
KDM4E B2RXH2 1/20 0.59
TUBB4A P04350 2/20 0.58
TUBB P07437 2/20 0.58
TUBA3C P0DPH7 2/20 0.58
TUBA1B P68363 2/20 0.58
TUBA4A P68366 2/20 0.58
TUBB4B P68371 2/20 0.58
TUBB3 Q13509 2/20 0.58
TUBB2A Q13885 2/20 0.58
TUBB8 Q3ZCM7 2/20 0.58
TUBA3E Q6PEY2 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423384 0.90 GPR119 (0.59) LMNATSHRSMN1; SMN2HTTNPSR1
SCHEMBL12580564 0.89 HDAC4 (0.56) LMNATSHRSMN1; SMN2HTTTUBB4A
SCHEMBL2901393 0.89 TUBB4A (0.58) LMNATSHRSMN1; SMN2TUBB4ATUBB
SCHEMBL4414448 0.89 GPR119 (0.56) LMNATSHRSMN1; SMN2L3MBTL1TUBB4A
SCHEMBL4414338 0.89 GPR119 (0.56) LMNATSHRSMN1; SMN2TUBB4ATUBB
SCHEMBL31260537 0.89 HDAC4 (0.56) LMNATSHRSMN1; SMN2TUBB4ATUBB
SCHEMBL4420449 0.89 LMNA (0.61) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL1653518 0.89 TUBB4A (0.60) LMNATSHRSMN1; SMN2TUBB4ATUBB
SCHEMBL32676791 0.89 EPHA2 (0.52) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL4415594 0.88 HTT (0.57) LMNATSHRMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 LMNA 4210/4885TSHR 222/4885MAPT 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.